Incidence of Adipose Tissue Alterations in First-Line Antiretroviral Therapy
Open Access
- 9 December 2002
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 162 (22) , 2621-2628
- https://doi.org/10.1001/archinte.162.22.2621
Abstract
ADIPOSE TISSUE alterations (ATAs) are a complex spectrum of manifestations that have been alternatively attributed to direct drug toxicity and to immunologic or endocrinologic events triggered by the treatment1-6; nevertheless, their cause and determinants have not yet been defined.This publication has 9 references indexed in Scilit:
- Clinical assessment of HIV-associated lipodystrophy in an ambulatory populationAIDS, 2001
- Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort studyPublished by Elsevier ,2001
- Adverse effects of antiretroviral therapyThe Lancet, 2000
- Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infectionAIDS, 2000
- Fat distribution and metabolic changes in patients with HIV infectionAIDS, 1999
- A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapyAIDS, 1999
- Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapyAIDS, 1999
- The effect of protease inhibitors on weight and body composition in HIV-infected patientsAIDS, 1998
- Potential factors affecting adherence with HIV therapyAIDS, 1997